2nd NovAliX Conference - Biophysics in Drug Discovery 2015

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

BφDD 2015

 Strasbourg, France    June 9-12, 2015

KEYNOTE LECTURE

Molecular Recognition in Protein-Ligand Complexes

Prof. Gerhard KLEBE
Prof. Gerhard KLEBE
PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany
Read more

INVITED LECTURES

SESSION 1: Method Development & Emerging Technologies

No Crystal, No Problem: Hydrogen Deuterium Exchange Mass Spectrometry in Drug Discovery

Dr Nino CAMPOBASSO
Dr Nino CAMPOBASSO
GLAXOSMITHKLINE, Collegeville, United States
Read more

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Dr Pär NORDLUND
Dr Pär NORDLUND
KAROLINSKA INSTITUTE & NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore
Read more

Second-Harmonic Generation (SHG) Measures and Resolves Protein Conformations: High-Throughput Structural Drug Discovery

Dr Joshua SALAFSKY
Dr Joshua SALAFSKY
BIODESY, South San Francisco, United States
Read more

SESSION 2: Biophysics for Integral Membrane Proteins

Fluorine NMR Screening: Principles and Application to a Membrane Protein

Dr Claudio DALVIT
Dr Claudio DALVIT
UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland
Read more

Improving the Biophysical Properties of GPCRs for Drug Screening and Structural Biology

Prof. Andreas PLÜCKTHUN
Prof. Andreas PLÜCKTHUN
UNIVERSITY OF ZÜRICH, Zurich, Switzerland
Read more

SESSION 3: Impact of Biophysics on Drug Discovery Projects

Biophysical Approaches for Hit Finding and Evaluation at Bayer

Dr Ursula EGNER
Dr Ursula EGNER
BAYER, Berlin, Germany
Read more

Making Every Interaction Count: Impact of Biophysical Methods Across the AstraZeneca Small-Molecule Portfolio

Dr Stefan GESCHWINDNER
Dr Stefan GESCHWINDNER
ASTRAZENECA, Mölndal, Sweden
Read more

Some Examples of Biophysics Helping Drug Discovery

Prof. Rod HUBBARD
Prof. Rod HUBBARD
UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom
Read more

Biophysics and Structural Biology Enabling the Discovery of Therapeutic Solutions: from Small Molecule Inhibitors to Vaccine Design

Dr Vincent MIKOL
Dr Vincent MIKOL
SANOFI, Vitry-sur-Seine, France
Read more

SESSION 4: The Use of Kinetics in Drug Discovery

CCR2 Antagonists: From Structure-Kinetics Relatiosnhips to in vivo Efficacy

Dr Laura HEITMAN
Dr Laura HEITMAN
UNIVERSITY OF LEIDEN, Leiden, The Netherlands
Read more

Towards a Better Understanding of the Structural Mechanisms of Kinase Inhibitor Binding Kinetics

Prof. Stefan KNAPP
Prof. Stefan KNAPP
OXFORD UNIVERSITY, Oxford, United Kingdom
Read more

Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure

Dr Herbert NAR
Dr Herbert NAR
BOEHRINGER INGELHEIM, Biberach, Germany
Read more

SESSION 5: Special Focus on Epigenetics

When to get Biophysical with Readers, Writers and Erasers

Dr Chun-wa CHUNG
Dr Chun-wa CHUNG
GLAXOSMITHKLINE, Stevenage, United Kingdom
Read more

Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics

Dr Robert A. COPELAND
Dr Robert A. COPELAND
EPIZYME, Cambridge, United States
Read more

Interrogating the Bromodomain Family Through Chemical Biology

Dr Richard CUMMINGS
Dr Richard CUMMINGS
CONSTELLATION PHARMACEUTICALS, Cambridge, United States
Read more

ORAL COMMUNICATIONS

Characterization of IL17A Inhibitors by Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS)

Mr Alfonso ESPADA
Mr Alfonso ESPADA
ELI LILLY, MADRID, Spain
Read more

A Universal Homogeneous Assay for High-Throughput Determination of Binding Kinetics

Dr Amaury Ernesto FERNANDEZ MONTALVAN
Dr Amaury Ernesto FERNANDEZ MONTALVAN
BAYER, Berlin, Germany
Read more

Drug Discovery at the Single Molecule Level

Dr Anders GUNNARSSON
Dr Anders GUNNARSSON
ASTRAZENECA, Mölndal, Sweden
Read more

First Crystal Structure of Transmembrane Domain of G-Protein-Coupled Receptor MGLU5 Provides Insight Into Efficient New Drugs Design

Dr Krzysztof OKRASA
Dr Krzysztof OKRASA
HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom
Read more

CDK8 Inhibitors with Long Residence Time Emerging from a Retro-Design Approach: New Opportunities for Cancer Treatment

Dr Anita WEGERT
Dr Anita WEGERT
MERCACHEM-SYNCOM, Nijmegen, The Netherlands
Read more

Strategies to Target Protein-Protein Interactions

Dr Marta WESTWOOD
Dr Marta WESTWOOD
UCB, Slough, United Kingdom
Read more